Drugs / REGN5713-5714-5715
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03969849 | Jun 2019 → Mar 2020 | ragweed sensitivity | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN5713-5714-5715 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03969849 ↗ |
| Known as | REGN5713/14/15 | “Bet v 1-specific antibody cocktail REGN5713/14/15” PMID 34126156 ↗ Jun 2021 |
| Modality | Protein / enzyme biologic | “Bet v 1-specific antibody cocktail” PMID 34126156 ↗ Jun 2021 |
| Route | Subcutaneous | “single subcutaneous (SC) dose” NCT03969849 ↗ |